Company intelligence / Profile preview
E-Star BioTech
Rochester, Minnesota, United Statese-star.bio ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
MANP has demonstrated a strong safety profile in multiple Phase 1 studies of participants with Hypertension, Resistant Hypertension, and Hypertension with comorbid Cardiometabolic Syndrome. The company dosed its first patient in a Phase 2 clinical trial (BOLD-HTN) in February 2025.[4][6]
- Therapeutic areas
- EndocrinologyCardiovascularMetabolic DisordersNephrology
- Modalities
- Designer peptidesNatriuretic Peptides
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Mayo Clinic
Beyond the preview
Go deeper on E-Star BioTech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E-Star BioTech.